Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report

Chi, Mau-Shin; Wu, Jen-Hong; Shaw, Suzun; Wu, Chin-Pyng; Chen, Liang-Kuang; Hsu, Ho-Chi; Chi, Kwan‐Hwa

doi:10.21037/tro-21-16

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The quality-of-life measurements had not revealed extra adverse effects of mEHT and even showed improvements in all functional and physiometric symptomatic scores. The preclinically approved immunogenic effects of mEHT [ 136 , 155 , 156 , 157 ], the human response studies [ 137 , 141 , 142 ], and the observed abscopal effects [ 138 , 143 , 144 ] probably promote the presented improvement of survival and QoL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Lee,

Lorant,

Grand

et al. 2023

Cancers

View full text Add to dashboard Cite

The mEHT method uses tissues’ thermal and bioelectromagnetic heterogeneity for the selective mechanisms. The success of the therapy for advanced, relapsed, and metastatic aggressive tumors can only be demonstrated by measuring survival time and quality of life (QoL). The complication is that mEHT-treated patients cannot be curatively treated any longer with “gold standards”, where the permanent progression of the disease, the refractory, relapsing situation, the organ failure, the worsening of blood counts, etc., block them. Collecting a cohort of these patients is frequently impossible. Only an intent-to-treat (ITT) patient group was available. Due to the above limitations, many studies have single-arm data collection. The Phase III trial of advanced cervix tumors subgrouping of HIV-negative and -positive patients showed the stable efficacy of mEHT in all patients’ subgroups. The single-arm represents lower-level evidence, which can be improved by comparing the survival data of various studies from different institutes. The Kaplan–Meier probability comparison had no significant differences, so pooled data were compared to other methods. Following this approach, we demonstrate the feasibility and superiority of mEHT in the cases of glioblastoma multiform, pancreas carcinomas, lung tumors, and colorectal tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A new therapeutic field is the complementarity application of checkpoint inhibitors (CPIs) combined with mEHT [ 141 , 142 ]. The immune action by CPI leads to a definite abscopal effect in clinical practice [ 143 , 144 ].…”

Section: Clinical Validationmentioning

confidence: 99%

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Lee,

Lorant,

Grand

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…However, the mEHT actively produces clinically observed abscopal phenomena. Following the preclinical studies of abscopal effects [ 108 , 109 , 124 , 125 ], case reports [ 126 , 127 , 128 , 129 ] demonstrated the clinical applicability. Some clinical studies validated the effects for various tumor entities [ 130 , 131 , 132 , 133 ].…”

Section: Clinical Evidence Of a Systemic Immune Effect Induced By Mehtmentioning

confidence: 99%

Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field

Minnaar

Szász

2022

Cells

View full text Add to dashboard Cite

The role of Heat Shock Proteins (HSPs) is a “double-edged sword” with regards to tumors. The location and interactions of HSPs determine their pro- or antitumor activity. The present review includes an overview of the relevant functions of HSPs, which could improve their antitumor activity. Promoting the antitumor processes could assist in the local and systemic management of cancer. We explore the possibility of achieving this by manipulating the electromagnetic interactions within the tumor microenvironment. An appropriate electric field may select and affect the cancer cells using the electric heterogeneity of the tumor tissue. This review describes the method proposed to effect such changes: amplitude-modulated radiofrequency (amRF) applied with a 13.56 MHz carrier frequency. We summarize the preclinical investigations of the amRF on the HSPs in malignant cells. The preclinical studies show the promotion of the expression of HSP70 on the plasma membrane, participating in the immunogenic cell death (ICD) pathway. The sequence of guided molecular changes triggers innate and adaptive immune reactions. The amRF promotes the secretion of HSP70 also in the extracellular matrix. The extracellular HSP70 accompanied by free HMGB1 and membrane-expressed calreticulin (CRT) form damage-associated molecular patterns encouraging the dendritic cells’ maturing for antigen presentation. The process promotes killer T-cells. Clinical results demonstrate the potential of this immune process to trigger a systemic effect. We conclude that the properly applied amRF promotes antitumor HSP activity, and in situ, it could support the tumor-specific immune effects produced locally but acting systemically for disseminated cells and metastatic lesions.

show abstract

The Immunogenic Connection of Thermal and Nonthermal Molecular Effects in Modulated Electro-Hyperthermia

Szász,

Lóránt,

Szász

et al. 2023

OJBIPHY

View full text Add to dashboard Cite

Hyperthermia in oncology is an emerging complementary therapy. The clinical results depend on multiple conditional factors, like the type of cancer, the stage, the applied treatment device, and the complementary conventional therapy. The molecular effect could also be different depending on the temperature, heating dose, kind of energy transfer, and timing sequences compared to the concomitant treatment. This article examines the molecular impacts of a specific technique used in oncological hyperthermia called modulated electro-hyperthermia (mEHT). What sets mEHT apart is its emphasis on harnessing the combined effects of thermal and nonthermal factors. Nonthermal energy absorption occurs through the excitation of molecules, while the thermal component ensures the ideal conditions for this process. The applied radiofrequency current selects the malignant cells, and the modulation drives the nonthermal effects to immunogenic cell death, helping to develop tumor-specific antitumoral immune reactions. The synergy of the thermal and nonthermal components excites the lipid-assembled clusters of transmembrane proteins (membrane rafts) as the channels of transient receptor potentials (TRPs), the heat-shock proteins (HSPs), the voltage-gated channels, and the voltage-sensitive phosphatases (VSPs). All these transmembrane compartments channeling various ionic species (like calcium and proton) interact with the cytoskeleton and are involved in the apoptotic signal pathways.

show abstract

Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report

Cited by 3 publications

References 11 publications

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field

The Immunogenic Connection of Thermal and Nonthermal Molecular Effects in Modulated Electro-Hyperthermia

Contact Info

Product

Resources

About